Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy.

Cancer discovery - 1 Feb 2017

Marabelle Aurelien, Aspeslagh Sandrine, Postel-Vinay Sophie, Soria Jean-Charles

Abstract excerpt

JAK mutations could be one of the primary escape mechanisms to anti-PD-1/PD-L1 immunotherapy via impaired IFNγ signaling in cancer cells and could be used to identify patients unlikely to benefit from these treatments. Cancer Discov; 7(2); 128-30. ©2017 AACR.See related article by Shin et al., p. 188.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Cancer Immunotherapy and Biomarkers
Share to Cytokine Signaling Pathways and Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Cell Function and Interaction

Share to Immunotherapy

Share to Janus Kinase 1

Share to Mutation

Share to Programmed Cell Death 1 Receptor

Source

Identifiers

PMID: 28167612
DOI: 10.1158/2159-8290.CD-16-1439

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy.PMID 28167612Read ↗

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.Semantic proximity Read ↗

Overcoming Genetically Based Resistance Mechanisms to PD-1 BlockadeSemantic proximity Read ↗

JAK Inhibition in STAT1 Gain-of-Function–Mediated Treatment-Resistant Autoimmune HepatitisSemantic proximity Read ↗

Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment.Semantic proximity Read ↗

Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is TargetableSemantic proximity Read ↗

Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance.Semantic proximity Read ↗

JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations.Semantic proximity Read ↗

JAK-ing up the Response to KIT Inhibition.Semantic proximity Read ↗

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?Semantic proximity Read ↗

Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.